Omega Fund VI, L.P. 3
3 · Imago BioSciences, Inc. · Filed Jul 15, 2021
Insider Transaction Report
Form 3
Omega Fund VI, L.P.
10% Owner
Holdings
Series B convertible Preferred Stock
→ Common Stock (2,275,909 underlying)Series C convertible Preferred Stock
→ Common Stock (492,828 underlying)
Footnotes (3)
- [F1]The shares of Series B and Series C convertible preferred stock shall automatically convert into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date.
- [F2]Reflects a 8.4-for-1 reverse stock split of the Issuer's outstanding securities effected prior to the effectiveness of the Issuer's S-1 Registration Statement.
- [F3]The reported securities are beneficially owned by Omega Fund VI, L.P. ("Omega VI"). The reported securities may be deemed to be beneficially owned by each of Omega Fund VI GP, L.P. ("Omega VI GP"), as the general partner of Omega VI, and Omega Fund VI GP Manager, Ltd. ("Omega VI GP Manager"), as the general partner of Omega VI GP. Otello Stampacchia, Claudio Nessi and Anne-Mari Paster are all the shareholders and directors of Omega VI GP Manager and have shared voting and investment power over the shares held by Omega VI and, as a result, may each be deemed to beneficially own the reported securities. Each of such individuals disclaims beneficial ownership of the shares held by Omega VI.